Physician profile
Lars Rikardsen
NPI 1558749226
$2,204.85
in general payments reported to CMS, 2019-2025
24 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.28 · 2021: $11.58 · 2022: $24.70 · 2023: $313 · 2024: $613 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.65 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $335.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $268.63 | 2019-2025 | |
| Lilly USA, LLC | $200.96 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $166.20 | 2023-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $118.08 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $115.53 | 2024-2025 | Airsupra |
| Inspire Medical Systems, INC. | $113.78 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $83.34 | 2024-2025 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.92 | 2024-2025 | Rexulti, Rejoyn |
| Otsuka America Pharmaceutical, INC. | $57.62 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $44.59 | 2024-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $31.25 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.61 | 2025 | Caplyta |
| Gilead Sciences, INC. | $25.50 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.02 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $20.21 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $20.18 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $20.04 | 2025 | Eliquis |
| Cranial Technologies, INC | $18.80 | 2025 | Doc Band |
| Abbott Laboratories | $14.58 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $14.02 | 2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $13.84 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lars Rikardsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.